Drug Profile

Research programme: lung disorder therapeutics - Rein Therapeutics/University of Texas Health Sciences Center at Tyler

Alternative Names: LTI-02; scuPA; Single chain urokinase plasminogen activator

Latest Information Update: 21 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

10 Jan 2025 Aileron Therapeutics is now called Rein Therapeutics
31 Oct 2023 Lung Therapeutics has been acquired and merged into Aileron Therapeutics
28 Nov 2018 No recent reports of development identified for preclinical development in Acute-lung-injury in USA (Inhalation)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com